Author Page for Mingxiang Zhang

Actions:

View:
Selected
Original List
All Versions Hide All Versions
All Abstracts Hide All Abstracts

(Rank)

Glecaprevir/Pibrentasvir to Treat Chronic Hepatitis C Virus Infection in Asia: Two Multicentre, Phase 3 Studies – A Randomised, Double-Blind Study (VOYAGE-1) and an Open-Label, Single-Arm Study (VOYAGE-2)

Number of pages: 44 Posted: 17 Jan 2020

Lai Wei, Guiqiang Wang, Negar N. Alami, Wen Xie, Jeong Heo, Qing Xie, Mingxiang Zhang, Yoon Jun Kim, Seng Gee Lim, Linda M. Fredrick, Wenjing Lu, Wei Liu, Hari V. Kalluri, Preethi Krishnan, Rakesh Tripathi, Niloufar Mobashery, Margaret Burroughs, Armen Asatryan, Jidong Jia and Jinlin Hou

Peking University - People’s Hospital, Peking University - Department of Infectious Diseases, AbbVie, Capital Medical University, Pusan National University, Shanghai Jiao Tong University (SJTU) - Department of Infectious Diseases, Government of the People's Republic of China - Sixth People's Hospital of Shenyang, Seoul National University - Department of Internal Medicine, National University of Singapore (NUS), Yong Loo Lin School of Medicine, Department of Medicine, AbbVie, AbbVie, AbbVie, AbbVie, AbbVie, AbbVie, AbbVie, AbbVie, AbbVie, Capital Medical University and Southern Medical University - State Key Laboratory of Organ Failure Research

Downloads 83 (783,685)

Mingxiang Zhang

Government of the People's Republic of China - Sixth People's Hospital of Shenyang

1

83

0

Scholarly Papers (1)

Glecaprevir/Pibrentasvir to Treat Chronic Hepatitis C Virus Infection in Asia: Two Multicentre, Phase 3 Studies – A Randomised, Double-Blind Study (VOYAGE-1) and an Open-Label, Single-Arm Study (VOYAGE-2)

Abstract: